Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial

P. M. Battezzati, M. Podda, S. Bruno, M. Zuin, A. Crosignani, M. Camisasca, A. Chiesa, M. L. Petroni, A. Russo, P. Gallotti, M. Borzio, F. Borzio, L. Buscarini, F. Fornari, G. Sbolli, A. Lanzini, M. G. Pigozzi, A. Salmi, G. Dastoli, P. L. Carriero

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To evaluate cost-effectiveness and response predictors of treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis, 263 consecutive patients were enrolled in a multicenter long-term study. A pre-planned analysis aimed at identifying predictors of early response was carried out when all patients had completed the initial 3 months of treatment with 6 MU thrice weekly. Sixty-three percent of the patients enrolled were classified as responders. At multivariate logistic regression analysis, baseline gamma-glutamyltranspeptidase levels and cirrhosis were the only independent variables significantly associated with response. The risk of no response after 3 months of treatment was 3.9 times higher (95% confidence interval, 1.6 to 7.2) in patients with high baseline levels of gammaglutamyl transpeptidase as compared with patients showing low baseline levels, and it was 2.0 times higher (1.1 to 3.8) in patients with cirrhosis as compared with those without it. We expect that results from this and other studies on large patient populations may help to select those patients who are more likely to benefit from interferon administration.

Original languageEnglish
Pages (from-to)481-484
Number of pages4
JournalItalian Journal of Gastroenterology
Volume24
Issue number9
Publication statusPublished - 1992

Fingerprint

Hepatitis
Therapeutics
Fibrosis
Peptidyl Transferases
interferon alfa-2a
Interferons
Cost-Benefit Analysis
Logistic Models
Regression Analysis
Confidence Intervals
Population

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. / Battezzati, P. M.; Podda, M.; Bruno, S.; Zuin, M.; Crosignani, A.; Camisasca, M.; Chiesa, A.; Petroni, M. L.; Russo, A.; Gallotti, P.; Borzio, M.; Borzio, F.; Buscarini, L.; Fornari, F.; Sbolli, G.; Lanzini, A.; Pigozzi, M. G.; Salmi, A.; Dastoli, G.; Carriero, P. L.

In: Italian Journal of Gastroenterology, Vol. 24, No. 9, 1992, p. 481-484.

Research output: Contribution to journalArticle

Battezzati, PM, Podda, M, Bruno, S, Zuin, M, Crosignani, A, Camisasca, M, Chiesa, A, Petroni, ML, Russo, A, Gallotti, P, Borzio, M, Borzio, F, Buscarini, L, Fornari, F, Sbolli, G, Lanzini, A, Pigozzi, MG, Salmi, A, Dastoli, G & Carriero, PL 1992, 'Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial', Italian Journal of Gastroenterology, vol. 24, no. 9, pp. 481-484.
Battezzati, P. M. ; Podda, M. ; Bruno, S. ; Zuin, M. ; Crosignani, A. ; Camisasca, M. ; Chiesa, A. ; Petroni, M. L. ; Russo, A. ; Gallotti, P. ; Borzio, M. ; Borzio, F. ; Buscarini, L. ; Fornari, F. ; Sbolli, G. ; Lanzini, A. ; Pigozzi, M. G. ; Salmi, A. ; Dastoli, G. ; Carriero, P. L. / Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. In: Italian Journal of Gastroenterology. 1992 ; Vol. 24, No. 9. pp. 481-484.
@article{68f63e49a54c4e9fa4229c6f38052d29,
title = "Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial",
abstract = "To evaluate cost-effectiveness and response predictors of treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis, 263 consecutive patients were enrolled in a multicenter long-term study. A pre-planned analysis aimed at identifying predictors of early response was carried out when all patients had completed the initial 3 months of treatment with 6 MU thrice weekly. Sixty-three percent of the patients enrolled were classified as responders. At multivariate logistic regression analysis, baseline gamma-glutamyltranspeptidase levels and cirrhosis were the only independent variables significantly associated with response. The risk of no response after 3 months of treatment was 3.9 times higher (95{\%} confidence interval, 1.6 to 7.2) in patients with high baseline levels of gammaglutamyl transpeptidase as compared with patients showing low baseline levels, and it was 2.0 times higher (1.1 to 3.8) in patients with cirrhosis as compared with those without it. We expect that results from this and other studies on large patient populations may help to select those patients who are more likely to benefit from interferon administration.",
author = "Battezzati, {P. M.} and M. Podda and S. Bruno and M. Zuin and A. Crosignani and M. Camisasca and A. Chiesa and Petroni, {M. L.} and A. Russo and P. Gallotti and M. Borzio and F. Borzio and L. Buscarini and F. Fornari and G. Sbolli and A. Lanzini and Pigozzi, {M. G.} and A. Salmi and G. Dastoli and Carriero, {P. L.}",
year = "1992",
language = "English",
volume = "24",
pages = "481--484",
journal = "Italian Journal of Gastroenterology",
issn = "0392-0623",
publisher = "Piccin Editore",
number = "9",

}

TY - JOUR

T1 - Factors predicint early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial

AU - Battezzati, P. M.

AU - Podda, M.

AU - Bruno, S.

AU - Zuin, M.

AU - Crosignani, A.

AU - Camisasca, M.

AU - Chiesa, A.

AU - Petroni, M. L.

AU - Russo, A.

AU - Gallotti, P.

AU - Borzio, M.

AU - Borzio, F.

AU - Buscarini, L.

AU - Fornari, F.

AU - Sbolli, G.

AU - Lanzini, A.

AU - Pigozzi, M. G.

AU - Salmi, A.

AU - Dastoli, G.

AU - Carriero, P. L.

PY - 1992

Y1 - 1992

N2 - To evaluate cost-effectiveness and response predictors of treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis, 263 consecutive patients were enrolled in a multicenter long-term study. A pre-planned analysis aimed at identifying predictors of early response was carried out when all patients had completed the initial 3 months of treatment with 6 MU thrice weekly. Sixty-three percent of the patients enrolled were classified as responders. At multivariate logistic regression analysis, baseline gamma-glutamyltranspeptidase levels and cirrhosis were the only independent variables significantly associated with response. The risk of no response after 3 months of treatment was 3.9 times higher (95% confidence interval, 1.6 to 7.2) in patients with high baseline levels of gammaglutamyl transpeptidase as compared with patients showing low baseline levels, and it was 2.0 times higher (1.1 to 3.8) in patients with cirrhosis as compared with those without it. We expect that results from this and other studies on large patient populations may help to select those patients who are more likely to benefit from interferon administration.

AB - To evaluate cost-effectiveness and response predictors of treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis, 263 consecutive patients were enrolled in a multicenter long-term study. A pre-planned analysis aimed at identifying predictors of early response was carried out when all patients had completed the initial 3 months of treatment with 6 MU thrice weekly. Sixty-three percent of the patients enrolled were classified as responders. At multivariate logistic regression analysis, baseline gamma-glutamyltranspeptidase levels and cirrhosis were the only independent variables significantly associated with response. The risk of no response after 3 months of treatment was 3.9 times higher (95% confidence interval, 1.6 to 7.2) in patients with high baseline levels of gammaglutamyl transpeptidase as compared with patients showing low baseline levels, and it was 2.0 times higher (1.1 to 3.8) in patients with cirrhosis as compared with those without it. We expect that results from this and other studies on large patient populations may help to select those patients who are more likely to benefit from interferon administration.

UR - http://www.scopus.com/inward/record.url?scp=0027008717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027008717&partnerID=8YFLogxK

M3 - Article

C2 - 1362657

AN - SCOPUS:0027008717

VL - 24

SP - 481

EP - 484

JO - Italian Journal of Gastroenterology

JF - Italian Journal of Gastroenterology

SN - 0392-0623

IS - 9

ER -